|
Atazanavir efficacy in covid-19: A retrospective protease inhibitors comparative study 2020
|
Ahmad Alikhani    , Mobin Ghazaiean , Roya Ghasemian , Mohammad Khademloo |
| Department of Infectious Diseases, Antimicrobial resistance research center and communicable disease institute, Mazandaran University of Medical Sciences, Sari, Iran , roya31gh@yahoo.com |
|
|
Abstract: (1773 Views) |
Background: Evaluation of protease inhibitors (PIs) is important in terms of prescribing an effective regimen for reducing mortality and hospitalization in Covid-19. Therefore, follow-up of patients better determines the characteristics of existing regimens.
Methods: We retrospectively evaluated the demographic, co-morbidities, gastrointestinal (GI) and liver complications of patients at two teaching hospitals from the first of March to the end of July 2020. All patients received one of two recommended regimens including hydroxychloroquine (HCQ) (400 mg BD on the first day and then 200 mg BD) plus atazanavir/ritonavir (ATV) (300/100 mg daily) or HCQ with the same dose plus lopinavir/ritonavir (Kaletra) (400/100 mg BD) for 5-7 days.
Results: We chose 170 cases that received 2 different regimens. In group one, 85(57.6% males) patients received Kaletra and HCQ and group two, 85 (55.3% males) patients received ATV and HCQ. The study for hospitalization in both groups showed no difference in more or less than 5 days hospitalization. (P=0.757) Comparison of mortality rates has not shown a significant difference including 19 (22.4%) deaths in group 1 and 15(17.6%) deaths in group 2 (P=0.443). Nausea followed by diarrhea was the most common side effects in group 1. But no side effects were reported in group 2 (P=0.000). Abnormal liver function tests (LFTs) were seen in both groups.
Conclusion: Comparison of hospitalization and mortality were not statistically significant. It seems that a respect to similar effect on mortality and hospitalization. ATV regimen is superior to Kaletra especially for better GI tolerance and less daily pills. |
|
| Keywords: Atazanavir / ritonavir, lopinavir / ritonavir, Side effects, Covid-19, Efficacy |
|
|
Full-Text [PDF 247 kb]
(434 Downloads)
|
Type of Study: Original Article |
Subject:
Infectious Diseases
Received: 2021/03/7 | Accepted: 2021/10/18 | Published: 2022/04/6
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
